Tactile Medical Q3 revenue $52.5M (+7% YoY), net loss $3.4M; cuts FY2021 guidance to $203.5-206M

TACTILE SYSTEMS TECHNOLOGY INC

2021-Q3 EPS reported -$0.22 revenue$146,329,000

Q3 revenue $52.5M (+7% YoY); net loss $3.4M ($0.17/share) vs net income $2.4M ($0.12) in Q3 2020.
Non-GAAP net loss $1.6M; Adjusted EBITDA $4.1M, down from $6.2M a year ago.
FY2021 revenue guidance cut to $203.5-206.0M (9-10% growth) from prior $216.3-224.5M (16-20%), citing Delta variant and labor shortages.
Acquired AffloVest respiratory therapy on Sept 8, funded with $30M term loan and $25M revolver draw; AffloVest added $0.9M revenue in Q3.
Cash $22.4M, total debt $55.0M under credit agreement as of Sept 30, 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.